Journos chronicle disregard for privacy, intimidation of whistleblowers at the VA

From long waits to manipulated medical records to preventable deaths, the Department of Veterans Affairs has had more than its share of problems over the past few years.

That’s no secret.

But did you know that employees and contractors at VA medical centers, clinics, pharmacies and benefit centers have committed upwards of 10,000 privacy violations since 2011?

It’s true, according to a recent analysis of VA data by ProPublica.

Worse still, a growing number of whistleblowers reporting the problems are under fire for doing the right thing.

“Some have reported being accused of violating HIPAA for collecting material to inform members of Congress about care problems at the VA,” according to a ProPublica article published Dec. 30. “Others say their own medical records were looked at by co-workers and officials without their consent.”

The article details a number of still more disturbing incidents, some of which seem lifted from the pages of an Oliver Stone script.

It also points to an effort to protect the whistleblowers—Connecticut Sen. Richard Blumenthal’s VA Patient Protection Act, which would bring the hammer down on VA supervisors who threaten, accuse or otherwise menace whistleblowers.

Blumenthal, the ranking Democrat on the Senate Committee on Veterans’ Affairs, introduced the measure in November and quickly won Republican backing for it.

“Nothing is more devastating and unconscionable than the misuse of power to subjugate legitimate complaints,” Blumenthal told ProPublica, adding that the VA has “a significant way to go in restoring trust and credibility.”

Click here to read the article and here for more on Blumenthal’s bill. 

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.